<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628692</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-062</org_study_id>
    <secondary_id>2012-000070-28</secondary_id>
    <nct_id>NCT01628692</nct_id>
  </id_info>
  <brief_title>Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus</brief_title>
  <official_title>A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy With Genotype 1 Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir
      with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who
      are treatment-naive or null responders to previous pegylated interferon/ribavirin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)</measure>
    <time_frame>Post Treatment Week 12 (Follow-up period)</time_frame>
    <description>SVR12 rate was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target detected or target not detected, at post-treatment Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>RVR was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at Week 4. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</measure>
    <time_frame>Week 12</time_frame>
    <description>cEVR was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>eRVR were defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at both Week 4 and Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With End of Treatment Response (EOTR)</measure>
    <time_frame>End of treatment (Week 24)</time_frame>
    <description>EOTR were defined as hepatitis C virus (HCV) RNA levels &lt;lower limit of quantitation, target not detected at end of treatment. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) by rs12979860 Single Nucleotide Polymorphisms in the IL-28B Gene Categories</measure>
    <time_frame>Baseline, post-treatment Week 12 (Follow-up period)</time_frame>
    <description>Participants were categorized into 3 genotypes based on single nucleotide polymorphisms in the IL28B gene. SVR12 was defined as hepatitis C virus (HCV) RNA levels below lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</measure>
    <time_frame>From start of treatment (Day 1) up to 7 days post last dose of study treatment (Week 24)</time_frame>
    <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Based on the severity, AEs were categorized as Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing &lt;75 kg received a total ribavirin dose of 1000 mg per day; those weighing &gt;=75 kg received 1200 mg per day) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing &lt;75 kg received a total ribavirin dose of 1000 mg per day; those weighing &gt;=75 kg received 1200 mg per day) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing &lt;75 kg received a total ribavirin dose of 1000 mg per day; those weighing &gt;=75 kg received 1200 mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablets, oral, 30 mg, once daily</description>
    <arm_group_label>Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir</arm_group_label>
    <arm_group_label>Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_label>Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_label>Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Capsule, oral, 150 mg, once daily</description>
    <arm_group_label>Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir</arm_group_label>
    <arm_group_label>Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_label>Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_label>Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <other_name>TMC435</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablets, oral, 500-600 mg, twice daily</description>
    <arm_group_label>Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
    <arm_group_label>Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Hepatitis C virus (HCV) genotype 1a or 1b

          -  Males and females, ≥18 years of age

          -  HCV RNA ≥10,000 IU/mL

          -  Participants with compensated cirrhosis are permitted

               -  Advanced fibrosis (F3/F4) is capped at approximately 35% of the total treated
                  population with a minimum of 20% F4 patients

               -  If no cirrhosis, a liver biopsy within 3 years prior to enrollment

               -  If cirrhosis is present, any prior liver biopsy

        Key Exclusion Criteria:

          -  Liver or any other transplant (other than cornea and hair)

          -  Evidence of a medical condition contributing to chronic liver disease other than HCV
             infection

          -  Current or known history of cancer, (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to enrollment

          -  Evidence of decompensated liver disease including, but not limited to, radiologic
             criteria, a history or presence of ascites, bleeding varices, or hepatic
             encephalopathy

          -  Patients infected with HIV or hepatitis B virus

          -  Gastrointestinal disease impacting absorption of study drug

          -  Uncontrolled diabetes or hypertension

          -  Prior exposure to an HCV direct-acting agent

          -  Any criteria that would exclude the patient from receiving ribavirin

          -  Absolute neutrophil count &lt;1.5*1,000,000,000 cells/L (&lt;1.2*1,000,000,000 cells/L for
             Black/African Americans)

          -  Platelets &lt;90*1,000,000,000 cells/L

          -  Hemoglobin &lt;12 g/dL for females, &lt;13 g/dL for males

          -  Alanine aminotransferase ≥5*upper limit of normal

          -  In patients without cirrhosis, total bilirubin ≥2 mg/dL unless patient has a
             documented history of Gilbert's disease

          -  In patients with cirrhosis, total bilirubin o ≥1.5 mg/dL

          -  International normalized ratio ≥1.7

          -  QTcF or QTcB &gt;500 mSec

          -  Creatinine clearance ≤50 mL/min

          -  Alpha fetoprotein (AFP) &gt;100 ng/mL OR

          -  AFP ≥50 ng/mL and ≤100 ng/mL requiring liver ultrasound

          -  Albumin &lt;3.5 g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute, Llc</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1119</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 08</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1126</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2012</study_first_posted>
  <results_first_submitted>August 13, 2015</results_first_submitted>
  <results_first_submitted_qc>October 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2015</results_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 25 centers in 6 countries.</recruitment_details>
      <pre_assignment_details>Of the 230 participants enrolled, 168 received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
          <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
        </group>
        <group group_id="P2">
          <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
          <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
        </group>
        <group group_id="P3">
          <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
          <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
        </group>
        <group group_id="P4">
          <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
          <description>Participants with hepatitis C virus genotype 1b, who never attained ≥2 log10 decline in hepatitis C virus RNA level after 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID were continued to receive treatment for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up period.</description>
        </group>
        <group group_id="P5">
          <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
          <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
          <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance/noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed 12 Week only</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis was performed on the treated participants defined as all randomized participants who received at least 1 dose of active study therapy.</population>
      <group_list>
        <group group_id="B1">
          <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
          <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
        </group>
        <group group_id="B2">
          <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
          <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
        </group>
        <group group_id="B3">
          <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
          <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
        </group>
        <group group_id="B4">
          <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
          <description>Participants with hepatitis C virus genotype 1b, who never attained ≥2 log10 decline in hepatitis C virus RNA level after 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID were continued to receive treatment for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up period.</description>
        </group>
        <group group_id="B5">
          <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
          <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
          <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;21 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21-&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C Virus RNA Distribution</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Randomization Stratum</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hepatitis C Virus Genotype 1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis C Virus Genotype 1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</title>
        <description>RVR was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at Week 4. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
        <time_frame>Week 4</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, who never attained ≥2 log10 decline in hepatitis C virus RNA level after 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID were continued to receive treatment for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</title>
          <description>RVR was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at Week 4. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
          <population>All treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="72.1" upper_limit="86.4"/>
                    <measurement group_id="O2" value="69.6" lower_limit="57.3" upper_limit="81.9"/>
                    <measurement group_id="O3" value="68.6" lower_limit="60.3" upper_limit="77.0"/>
                    <measurement group_id="O4" value="85" lower_limit="74.8" upper_limit="95.2"/>
                    <measurement group_id="O5" value="75" lower_limit="59.0" upper_limit="91.0"/>
                    <measurement group_id="O6" value="33.3" lower_limit="13.2" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Early Virologic Response (cEVR)</title>
        <description>cEVR was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
        <time_frame>Week 12</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Early Virologic Response (cEVR)</title>
          <description>cEVR was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
          <population>All treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="78.6" upper_limit="91.2"/>
                    <measurement group_id="O2" value="73.9" lower_limit="62.2" upper_limit="85.6"/>
                    <measurement group_id="O3" value="82.4" lower_limit="75.5" upper_limit="89.2"/>
                    <measurement group_id="O4" value="90" lower_limit="81.4" upper_limit="98.6"/>
                    <measurement group_id="O5" value="66.7" lower_limit="49.2" upper_limit="84.1"/>
                    <measurement group_id="O6" value="11.1" lower_limit="0" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)</title>
        <description>SVR12 rate was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target detected or target not detected, at post-treatment Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
        <time_frame>Post Treatment Week 12 (Follow-up period)</time_frame>
        <population>All participants who were randomized and received at least 1 dose of active study therapy (daclatasvir, simeprevir, ribavirin).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)</title>
          <description>SVR12 rate was defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target detected or target not detected, at post-treatment Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
          <population>All participants who were randomized and received at least 1 dose of active study therapy (daclatasvir, simeprevir, ribavirin).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="78.6" upper_limit="91.2"/>
                    <measurement group_id="O2" value="69.6" lower_limit="57.3" upper_limit="81.9"/>
                    <measurement group_id="O3" value="74.5" lower_limit="66.7" upper_limit="82.3"/>
                    <measurement group_id="O4" value="95" lower_limit="88.8" upper_limit="100"/>
                    <measurement group_id="O5" value="66.7" lower_limit="49.2" upper_limit="84.1"/>
                    <measurement group_id="O6" value="0">As none of the participants responded to SVR12, 80% confidence interval value is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</title>
        <description>eRVR were defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at both Week 4 and Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, who never attained ≥2 log10 decline in hepatitis C virus RNA level after 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID were continued to receive treatment for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</title>
          <description>eRVR were defined as hepatitis C virus (HCV) RNA levels to be &lt;lower limit of quantitation, target not detected at both Week 4 and Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
          <population>All treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="63.8" upper_limit="79.6"/>
                    <measurement group_id="O2" value="60.9" lower_limit="47.8" upper_limit="73.9"/>
                    <measurement group_id="O3" value="62.7" lower_limit="54.1" upper_limit="71.4"/>
                    <measurement group_id="O4" value="75" lower_limit="62.6" upper_limit="87.4"/>
                    <measurement group_id="O5" value="58.3" lower_limit="40.1" upper_limit="76.6"/>
                    <measurement group_id="O6" value="11.1" lower_limit="0" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With End of Treatment Response (EOTR)</title>
        <description>EOTR were defined as hepatitis C virus (HCV) RNA levels &lt;lower limit of quantitation, target not detected at end of treatment. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
        <time_frame>End of treatment (Week 24)</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, who never attained ≥2 log10 decline in hepatitis C virus RNA level after 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID were continued to receive treatment for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With End of Treatment Response (EOTR)</title>
          <description>EOTR were defined as hepatitis C virus (HCV) RNA levels &lt;lower limit of quantitation, target not detected at end of treatment. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
          <population>All treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="83.1" upper_limit="94.3"/>
                    <measurement group_id="O2" value="78.3" lower_limit="67.2" upper_limit="89.3"/>
                    <measurement group_id="O3" value="78.4" lower_limit="71.1" upper_limit="85.8"/>
                    <measurement group_id="O4" value="95" lower_limit="88.8" upper_limit="100"/>
                    <measurement group_id="O5" value="66.7" lower_limit="49.2" upper_limit="84.1"/>
                    <measurement group_id="O6" value="0">As none of the participants responded at EOT, hence 80% confidence interval value is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) by rs12979860 Single Nucleotide Polymorphisms in the IL-28B Gene Categories</title>
        <description>Participants were categorized into 3 genotypes based on single nucleotide polymorphisms in the IL28B gene. SVR12 was defined as hepatitis C virus (HCV) RNA levels below lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
        <time_frame>Baseline, post-treatment Week 12 (Follow-up period)</time_frame>
        <population>All treated participants. Here ‘n’ signifies those participants evaluable for this measure at specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal QD, for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1b. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1b, who never attained ≥2 log10 decline in hepatitis C virus RNA level after 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID were continued to receive treatment for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Naive)</title>
            <description>Participants with no prior treatment of hepatitis C virus genotype 1a. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Genotype 1a: Daclatasvir + Simeprevir + Ribavirin (Null)</title>
            <description>Participants with hepatitis C virus genotype 1a, who never attained ≥2 log10 decline in hepatitis C virus genotype RNA level after 12 weeks of prior therapy. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) by rs12979860 Single Nucleotide Polymorphisms in the IL-28B Gene Categories</title>
          <description>Participants were categorized into 3 genotypes based on single nucleotide polymorphisms in the IL28B gene. SVR12 was defined as hepatitis C virus (HCV) RNA levels below lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.</description>
          <population>All treated participants. Here ‘n’ signifies those participants evaluable for this measure at specified time points for each group, respectively.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL28B Genotype CC type (n= 16,1,13,1,3,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="84.6"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="NA">As no participant was evaluable for assessment, hence value is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL28B Genotype CT type (n= 22,15, 28,10,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="82.1"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL28B Genotype TT type (n= 12,6,10,7,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="NA">No participants were available for assessment</measurement>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</title>
        <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Based on the severity, AEs were categorized as Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.</description>
        <time_frame>From start of treatment (Day 1) up to 7 days post last dose of study treatment (Week 24)</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 1b: Daclatasvir + Simeprevir (Naive + Null)</title>
            <description>Participants with and without prior treatment of hepatitis C virus genotype 1b and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Genotype1b: Daclatasvir +Simeprevir + Ribavirin (Naive + Null)</title>
            <description>Participants with and without prior treatment of hepatitis C virus genotype 1b and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Genotype1a: Daclatasvir +Simeprevir + Ribavirin(Naive + Null)</title>
            <description>Participants with and without prior treatment of hepatitis C virus genotype 1a and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</title>
          <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Based on the severity, AEs were categorized as Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.</description>
          <population>All treated participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment (Day 1) up to 7 days post last dose of study treatment (Week 24)</time_frame>
      <desc>On-Treatment Period</desc>
      <group_list>
        <group group_id="E1">
          <title>Genotype 1b: Daclatasvir + Simeprevir (Naive + Null)</title>
          <description>Participants with and without prior treatment of hepatitis C virus genotype 1b and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food and simeprevir 150 mg with a light to standard meal once daily (QD), for a period of 12 weeks or 24 weeks based on re-randomization and continued into a post-treatment follow-up period.</description>
        </group>
        <group group_id="E2">
          <title>Genotype1b: Daclatasvir +Simeprevir + Ribavirin (Naive + Null)</title>
          <description>Participants with and without prior treatment of hepatitis C virus genotype 1b and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;= 75 kg, respectively) ribavirin twice daily (BID) for a period of 12 or 24 weeks based on re-randomization and continued into post-treatment follow-up.</description>
        </group>
        <group group_id="E3">
          <title>Genotype1a: Daclatasvir +Simeprevir + Ribavirin (Naive + Null)</title>
          <description>Participants with and without prior treatment of hepatitis C virus genotype 1a and who never attained ≥2 log10 decline in hepatitis C virus RNA levels after at least 12 weeks of prior therapy with peginterferon/ribavirin. Received daclatasvir 30 mg with or without food, simeprevir 150 mg with a light to standard meal QD, and weight stratified (1000/1200 mg for participants weighing &lt;75/&gt;=75 kg, respectively) ribavirin BID for a period of 24 weeks and continued into post-treatment follow-up period of 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

